Jounce Therapeutics (NASDAQ:JNCE) is scheduled to issue its quarterly earnings data before the market opens on Tuesday, November 13th. Analysts expect the company to announce earnings of ($0.34) per share for the quarter.

Jounce Therapeutics (NASDAQ:JNCE) last issued its earnings results on Friday, August 10th. The company reported ($0.14) earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.37) by $0.23. The business had revenue of $19.38 million for the quarter, compared to analyst estimates of $12.47 million. Jounce Therapeutics had a negative net margin of 50.54% and a negative return on equity of 23.27%. On average, analysts expect Jounce Therapeutics to post $-1 EPS for the current fiscal year and $-1 EPS for the next fiscal year.

Shares of NASDAQ JNCE opened at $4.81 on Friday. The firm has a market cap of $178.47 million, a P/E ratio of -8.44 and a beta of 4.97. Jounce Therapeutics has a 12-month low of $4.03 and a 12-month high of $29.25.

Several research firms have weighed in on JNCE. Zacks Investment Research upgraded shares of Jounce Therapeutics from a “hold” rating to a “buy” rating and set a $6.50 price objective on the stock in a report on Tuesday, October 16th. HC Wainwright set a $13.00 price objective on shares of Jounce Therapeutics and gave the stock a “buy” rating in a report on Monday, August 13th. JPMorgan Chase & Co. lowered their price objective on shares of Jounce Therapeutics from $12.00 to $10.00 and set a “hold” rating on the stock in a report on Friday, August 10th. Cowen restated a “hold” rating on shares of Jounce Therapeutics in a report on Thursday, August 9th. Finally, ValuEngine upgraded shares of Jounce Therapeutics from a “sell” rating to a “hold” rating in a report on Thursday, August 2nd. Four investment analysts have rated the stock with a hold rating and four have assigned a buy rating to the stock. The company currently has an average rating of “Buy” and an average target price of $11.92.

COPYRIGHT VIOLATION WARNING: This news story was originally reported by TheOlympiaReport and is owned by of TheOlympiaReport. If you are viewing this news story on another site, it was illegally copied and republished in violation of international trademark and copyright laws. The correct version of this news story can be read at

About Jounce Therapeutics

Jounce Therapeutics, Inc, a clinical stage immunotherapy company, develops therapies for the treatment of cancer. Its lead product candidate is JTX-2011, a clinical stage monoclonal antibody that binds to and activates the inducible T cell co-stimulator, a protein on the surface of certain T cells found in solid tumors, which is in Phase I/II clinical trial for the treatment of six tumor types, including head and neck squamous cell cancer, non-small cell lung cancer, triple negative breast cancer, melanoma, gastric cancer, and other tumor types identified through its translational science platform.

Further Reading: What is a Call Option?

Earnings History for Jounce Therapeutics (NASDAQ:JNCE)

Receive News & Ratings for Jounce Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Jounce Therapeutics and related companies with's FREE daily email newsletter.